What is Crossject?
Crossject Société Anonyme is a French-based biotechnology firm specializing in the engineering of needle-free injection devices. Its flagship platform, ZENEO, provides a sophisticated alternative to traditional delivery methods, specifically targeting patient-side management for conditions requiring rapid or self-administered intervention. The company's diverse portfolio addresses critical medical needs, including treatments for epileptic seizures, opioid overdoses, severe asthma, anaphylactic shock, and various chronic conditions such as rheumatoid arthritis and migraines. By eliminating the need for needles, Crossject aims to improve patient compliance and safety, positioning itself as a transformative force in the drug delivery market.
How much funding has Crossject raised?
Crossject has raised a total of $60.4M across 6 funding rounds:
Debt
$12M
Unspecified
$7.6M
Multiple Rounds
$23.5M
Stock/Share Issuance
$17.3M
Debt (2020): $12M, investors not publicly disclosed
Unspecified (2024): $7.6M led by Agence nationale de la recherche ANR
Stock/Share Issuance (2025): $6.4M, investors not publicly disclosed
Other Financing Round (2025): $11.3M featuring Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $5.8M backed by Vatel Capital
Stock/Share Issuance (2026): $17.3M, investors not publicly disclosed
Key Investors in Crossject
Agence nationale de la recherche ANR
The ANR is the French national agency responsible for funding project-based research across various scientific disciplines, supporting innovation in public health and engineering.
Biomedical Advanced Research and Development Authority (BARDA)
BARDA enhances public health security by facilitating the development of innovative medical countermeasures, partnering with innovators to bring therapeutics from preclinical stages to market.
Vatel Capital
Vatel Capital is a French financial firm that provides personalized investment strategies and tax management services, focusing on supporting growth-oriented enterprises.
What's next for Crossject?
With the recent influx of capital, Crossject is well-positioned to scale its manufacturing capabilities and advance its regulatory milestones for its core product pipeline. The strategic focus will likely shift toward the global commercialization of its ZENEO devices, particularly in markets where patient-side management of acute crises is a priority. As the company transitions into a more mature enterprise phase, the integration of these funds will be pivotal in navigating the complex regulatory landscape and expanding its footprint in the international healthcare sector. Future growth will be driven by the successful deployment of its therapeutic solutions and the continued validation of its needle-free technology by global health authorities.
See full Crossject company page
